A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH) during a clinical trial in China. Participants on the drug saw better liver outcomes and fewer side effects than those on a placebo. Although more research is needed, especially in diverse populations, this finding hints at a transformative role for existing medications in tackling liver diseases.
from Top Health News -- ScienceDaily https://ift.tt/wkv36OY
No comments:
Post a Comment